The association between calreticulin and glucagon-like peptide-1 expressionswith prognostic factors in high-grade gliomas

The association between calreticulin and glucagon-like peptide-1 expressionswith prognostic factors in high-grade gliomas

Bibliographic Details
Main Authors:	O. Baran, A. Kayhan, S. Evran, N. Demirel, D. Sonmez, H. Serin, G. Akyoldas, A. Kocak, R. Kemerdere, T. Tanriverdi
Format:	Article
Language:	English
Published:	Elsevier 2022-01-01
Series:	Brain and Spine
Online Access:	http://www.sciencedirect.com/science/article/pii/S2772529422006373

Similar Items

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration
by: Markus Ammann, et al.
Published: (2023-09-01)

New insights into the regulation of glucagon secretion by glucagon-like peptide-1.
by: Gromada, J, et al.
Published: (2004)

Glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists in the treatment of type 2 diabetes
by: Seungah Lee, et al.
Published: (2017-03-01)

Glucagon-like peptide-1 analogues: An overview
by: Vishal Gupta
Published: (2013-01-01)

Glucagon-like peptide 1 (GLP-1)
by: T.D. Müller, et al.
Published: (2019-12-01)

Calreticulin and the Heart
by: Jody Groenendyk, et al.
Published: (2022-05-01)

Glucagon‐like peptide agonists: A prospective review
by: Zamara Mariam, et al.
Published: (2024-01-01)

Equine glucagon-like peptide-1 receptor physiology
by: Murad H. Kheder, et al.
Published: (2018-01-01)

Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1
by: Silvano Paternoster, et al.
Published: (2018-10-01)

Prognostic Factors of Low-Grade Gliomas in Adults
by: Mariana Deacu, et al.
Published: (2022-09-01)

Calreticulin: Challenges Posed by the Intrinsically Disordered Nature of Calreticulin to the Study of Its Function
by: Lilian Varricchio, et al.
Published: (2017-11-01)

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects
by: Takaaki Murakami, et al.
Published: (2020-11-01)

Investigating the Glucagon Receptor and Glucagon-Like Peptide 1 Receptor Activity of Oxyntomodulin-Like Analogues in Male Wistar Rats
by: Samantha L. Price, MRes, et al.
Published: (2015-12-01)

Dissecting the potential role of calreticulin as a prognostic biomarker for invasive breast cancer
by: Mehdi, Sabaghpour Azarian Mohammad
Published: (2020)

Glucagon-like peptide 1 stimulates hypothalamic proopiomelanocortin neurons.
by: Ma, X, et al.
Published: (2007)

Nephroprotective potential of glucagon-like peptide-1 receptor agonists
by: Minara S. Shamkhalova, et al.
Published: (2020-04-01)

Glucagon-like Peptide-1 Secretion Is Inhibited by Lysophosphatidic Acid
by: Maria F. Fernandes, et al.
Published: (2022-04-01)

Pharmacogenetics of Glucagon-like-peptide-1 receptor in diabetes management
by: Mariya Kalinkova, et al.
Published: (2023-06-01)

Glucagon-Like Peptide-1: A Focus on Neurodegenerative Diseases
by: Maddalena Grieco, et al.
Published: (2019-10-01)

Glucagon-like peptide 1 and dysglycemia: Conflict in incretin science
by: Awadhesh Kumar Singh
Published: (2015-01-01)

Efficacy of glucagon-like peptide-1 mimetics for neural regeneration
by: Kazunori Sango, et al.
Published: (2015-01-01)

Cardiovascular Effects of Glucagon-Like Peptide-1 Receptor Agonists
by: Yu Mi Kang, et al.
Published: (2016-06-01)

GRK Inhibition Potentiates Glucagon-Like Peptide-1 Action
by: Seunghun P. Lee, et al.
Published: (2021-05-01)

Bioactivity of a modified human Glucagon-like peptide-1.
by: Fangfang Xu, et al.
Published: (2017-01-01)

How glucagon-like peptide 1 receptor agonists work
by: Christine Rode Andreasen, et al.
Published: (2021-07-01)

The prognostic factors and nomogram for patients with high-grade gliomas
by: Shanqiang Qu, et al.
Published: (2021-11-01)

Production and Characterization of Peptide Antibodies to the C-Terminal of Frameshifted Calreticulin Associated with Myeloproliferative Diseases
by: Farah Perveen Mughal, et al.
Published: (2022-06-01)

Mutant Calreticulin in the Myeloproliferative Neoplasms
by: Daniel Prins, et al.
Published: (2020-02-01)

The many faces of parasite calreticulin
by: Diego Esperante, et al.
Published: (2023-03-01)

Calreticulin induces dilated cardiomyopathy.
by: Dukgyu Lee, et al.
Published: (2013-01-01)

The Road towards Triple Agonists: Glucagon-Like Peptide 1, Glucose-Dependent Insulinotropic Polypeptide and Glucagon Receptor - An Update
by: Agnieszka Jakubowska, et al.
Published: (2024-02-01)

Salivary Hormones Leptin, Ghrelin, Glucagon, and Glucagon-Like Peptide 1 and Their Relation to Sweet Taste Perception in Diabetic Patients
by: Nada K. Al-Ghurayr, et al.
Published: (2023-01-01)

Extremely rare complication of granulomatosis with polyangiitis
by: Oguz Baran, et al.
Published: (2019-12-01)

Radiosensitization of calreticulin‐overexpressing human glioma cell line by the polyphenolic acetate 7, 8‐diacetoxy‐4‐methylcoumarin
by: Amit Verma, et al.
Published: (2022-12-01)

Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.
by: Armstrong, M, et al.
Published: (2015)

Glucagon-like peptide-1: regulation of insulin secretion and therapeutic potential.
by: Gromada, J, et al.
Published: (2004)

Special Issue: “Anti-inflammatory Effects of Glucagon-like Peptide-1”
by: Alessandra Puddu, et al.
Published: (2024-02-01)

Conformational Dynamics of Glucagon-like Peptide-2 with Different Electric Field
by: Jingjie Su, et al.
Published: (2022-07-01)

Immunohistochemical Glucagon-like Peptide-1 Receptor Expression in Human Insulinomas
by: Tiina Vesterinen, et al.
Published: (2023-10-01)

Glucagon-like peptide-1 receptor agonists in patients treated with antipsychotics
by: A. Delgado, et al.
Published: (2021-04-01)